An investigation on behalf of current long term investors in Lipocine Inc (NASDAQ:LPCN) shares over possible breaches of fiduciary duty by certain officers and directors was announced
San Diego, CA -- (SBWIRE) -- 02/05/2018 -- An investigation on behalf of investors in shares of Lipocine Inc (NASDAQ:LPCN) concerning potential breaches of fiduciary duties by certain directors and officers of Lipocine Inc was announced.
Investors who are current long term investors in Lipocine Inc (NASDAQ:LPCN) shares, have certain options and should contact the Shareholders Foundation at email@example.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in NASDAQ:LPCN stocks follows a lawsuit filed against Lipocine Inc over alleged securities laws violations. The investigation on behalf of current long term investors in NASDAQ:LPCN stocks, concerns whether certain Lipocine officers and directors are liable in connection with the allegations made in that lawsuit.
According to that complaint filed in the U.S. District Court for the District of New Jersey the plaintiff alleges that the defendants made allegedly false and/or misleading statements and/or failed to disclose that Lipocine's filing of its New Drug Application to the U.S. Food and Drug Administration for LPCN 1021, Lipocine's lead product candidate, contained deficiencies, and that as a result, defendants' statements about Lipocine's business and operations were false and misleading and/or lacked a reasonable basis.
On June 29, 2016, Lipocine Inc announced that it has received a Complete Response Letter ("CRL") from the United States Food and Drug Administration ("FDA") regarding its New Drug Application ("NDA") for LPCN 1021, an oral testosterone product candidate for testosterone replacement therapy ("TRT") in adult males for conditions associated with a deficiency or absence of endogenous testosterone, also known as hypogonadism. Lipocine Inc said that the CRL identified deficiencies related to the dosing algorithm for the label. More specifically, Lipocine Inc said that the CRL stated that the proposed titration scheme for clinical practice was significantly different from the titration scheme used in the Phase 3 trial leading to discordance in titration decisions between the Phase 3 trial and real-world clinical practice.
Those who purchased shares of Lipocine Inc (NASDAQ:LPCN) have certain options and should contact the Shareholders Foundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North - Suite 423
92108 San Diego
For more information on this press release visit:
Media Relations Contact
Email: Click to Email Michael Daniels